ProfessorDeborah Ashby

RSS President's Address 2019- Pigeon-holes and mustard seeds: Growing capacity to use data for Society

Plenary Talk

“A Statistician’s Adventure in Wonderland:Using Statistical Theory,Epidemiology and Clinical Trials for Public Health Impact”

Invited to participate as a speaker by DIA Pharmacovigilance and Risk Management Strategies Conference on "Aspects of Benefit-Risk Assessment"

Invited speaker HRB-TMRN 4th Annual Trial Methodology Symposium 2018 on “Methodological innovations in randomised trials” Galway, October 2018

Lancaster University Data Science Institute Distinguished Lecture ‘Better benefit-risk decision-making in the regulation of medicines: new opportunities for statistical and data sciences’ Lancaster April 2018

Athena Swan lecture ‘A Statistician’s Adventures in Wonderland: Using Statistical Theory, Epidemiology and Clinical Trials for Public Health Impact’ London February 2018

Dean’s Distinguished Lecture, University of Warwick ‘Using Statistical Theory, Epidemiology and Clinical Trials for Public Health Impact’ Coventry, February 2018

Definitive Intervention and Feasibility Awards Panel

Invited as a keynote speaker by the University of Liverpool to talk on The Importance of Outliers.

Invited to give a Keynote presentation on Clinical Trials for Health Technology Assessment Past, Present and Future

Invited to give a talk at the Bayesian Biostatistics Workshop ,Cambridge on Bayesian approaches in the regulation of medicines: current and future potential.

Opening Keynote speaker at 2017 ASA American Statistical Association Biopharmaceutical Section Regulatory-Industry Statistics Workshop on ‘Patient-centric benefit-risk decision-making in the regulation of medicines’ Washington DC, September 2017

NIHR Strategic Review of Training Advisory Group

The Stephen Frankel Lecture at the University of Bristol on ‘Using Statistical Theory, Epidemiology and Clinical Trials to PROTECT Population Health’, Bristol, December 2016

Keynote talk at the Annual meeting of the Network of Hubs for Trials Methodology Research on ‘Formal approaches to benefit-risk decision-making in licensing of medicines and other therapies’ Cambridge, November 2016

NIHR HTA Programme

Invited speaker at American Statistical Association Biopharmaceutical Section Statistical Workshop on ‘What role should formal risk-benefit decision-making play in the regulation of medicines?’ Washington DC, September 2015

Doctoral training Partnerships Panel

IDEAS (Improving Drug Development) External Advisory Panel, 2015-Date

Scientific Committee, Glasgow 2015

Expert review committee for the Major Sciences Initiatives